Xinhua Silk Road : le marathon de Shenyang, dans le nord-est de la Chine, attire les amateurs de course à pied venus de tout le pays et de l'étranger

PÉKIN,/PRNewswire/ -- Le marathon de Shenyang 2026, organisé par la Shengjing Bank Shenyang, a débuté dimanche matin, attirant environ 22 000 passionnés de course à pied venus de Chine et de l'étranger à Shenyang, capitale de la province du Liaoning, dans le nord-est de la Chine, pour cet événement de plus en plus international.

Le marathon complet a réuni 10 000 coureurs et le semi-marathon 12 000, tous partis du Centre sportif olympique de Shenyang tôt dans la matinée du 6 septembre.

Dans le marathon masculin, c'est un coureur kenyan qui a terminé premier, tandis que la course féminine a été remportée par une coureuse éthiopienne. Dans les épreuves de semi-marathon, les titres masculins et féminins ont été remportés par des coureurs chinois, Zhang Xiaorui et Zhao Na.

Tout en offrant un cadre propice aux épreuves de vitesse, le marathon de Shenyang a également mobilisé 30 coureurs titulaires d'un diplôme de secourisme pour accompagner les coureurs âgés, les participants malvoyants et les athlètes en fauteuil roulant.

Grâce à cet accompagnement réconfortant, le marathon de Shenyang a parfaitement illustré comment un événement sportif permet de mettre en avant les valeurs d'égalité, de courage et de solidarité.

Cette année, le marathon de Shenyang a mis à l'honneur des slogans rédigés dans le style des dialectes du nord-est de la Chine, affichés aux différents points du parcours, tels que « Laotie n'abandonne jamais », afin d'encourager les coureurs à persévérer.

Ces slogans, imprégnés des particularités de la langue locale, mettaient non seulement en avant les traits de caractère typiques des habitants du nord-est de la Chine, tels que la franchise, l'optimisme, la résilience et le sens du travail, mais faisaient également écho à l'énergie des groupes d'encouragement locaux présents le long du parcours.

En organisant des spectacles de danse sur le thème de l'industrie lourde, des danses folkloriques Yangge et d'autres représentations tout au long des parcours, les « équipes de supporters Laotie » – des groupes de supporters amicaux – ont créé une expérience immersive de soutien dans toute la ville.

Parmi les nombreux sites où les équipes encourageaient les coureurs, un « couloir d'encouragement » de 100 mètres de long, aménagé sur un pont local enjambant la rivière Hun, a impressionné les coureurs avec une foule nombreuse de habitants venus eux aussi profiter de l'enthousiasme qui régnait à Shenyang.

Chaque participant à l'événement a reçu un « passeport touristique culturel » local, lui permettant de se promener en ville afin de découvrir une douzaine de sites touristiques populaires de Shenyang.

L'entrée au Palais impérial de Shenyang, au musée de l'ancienne résidence de Zhang Xueliang et au musée financier de Shenyang sera gratuite du 5 au 11 septembre ; les coureurs venus de Chine et de l'étranger y trouveront sans doute les services touristiques « de niveau Laotie » plus qu'accueillants.

Lien original : https://en.imsilkroad.com/p/352088.html

Share this article

Mancini Recognized in Fast Company's 2026 100 Best Workplaces for Innovators

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- Mancini, a national architecture and design firm with a 110-year history, has earned the No. 69 position on Fast Company's 2026 list of the 100 Best Workplaces for Innovators.

The annual awards recognize organizations that give employees at every level the freedom, resources, and support to develop ideas that move their industries forward. Mancini was selected for a culture that empowers its architects and designers to look critically at how they work, identify opportunities for improvement, and build their own solutions.

At Mancini, innovation does not sit within a separate technology department. It comes directly from inside the practice. The people designing buildings are also designing the systems through which those buildings are imagined, tested, and delivered. Many of the firm's most transformative technologies began with employees questioning an everyday process and being given the opportunity to develop a better one.

"The people closest to the work understand its challenges better than anyone else, so we give our team the freedom to solve them," said Christian Giordano, President of Mancini. "Our responsibility as leaders is to give people the time and resources to pursue a good idea, remove the red tape, and trust them to take it somewhere. That is how innovation becomes part of a company's culture rather than simply something it talks about."

This philosophy led to the creation of Mancini's Design Lab, an internal incubator that brings together people from across the firm to explore emerging technologies, test ideas, and turn promising concepts into practical tools. It has also enabled architects and designers without traditional software development backgrounds to teach themselves new skills and create enterprise-level platforms tailored specifically to the needs of an architecture firm.

Among those innovations is MIKA, the Mancini Information and Knowledge Assistant, an internally developed AI platform that connects critical knowledge and workflows across the firm. What began as a response to an everyday operational challenge has grown into a broader system designed around how architects and designers actually work.

Mancini also developed and patented The Toolbelt, a suite of virtual and augmented reality technologies that allows project teams and clients to enter, experience, and modify designs in real time. Through the firm's 360 Design Sessions, clients can understand spatial relationships, test options, and make informed decisions much earlier in the design process. Those decisions are reflected directly in the project model, strengthening alignment, accelerating approvals, and reducing costly revisions later.

Together, these tools represent more than an investment in technology. They reflect Mancini's belief that a workplace becomes innovative when employees are trusted to challenge established processes and given a meaningful role in shaping what comes next.

Mancini joins companies including Google, Chipotle, Morgan Stanley, and GE among Fast Company's 2026 honorees.

The recognition follows another period of significant growth for Mancini. The firm ranked No. 52 on Interior Design's 2026 Top 100 Giants list and No. 25 on its 2026 Hospitality Giants list, rising 21 positions from No. 46 in 2025.

ABOUT MANCINI

Mancini Duffy is a national award-winning design firm with a legacy spanning over 100 years. Headquartered in New York City, Mancini has regional offices in Millburn and Red Bank, New Jersey, Phoenix, Arizona, Seattle, Washington, Tampa, West Palm Beach, Florida. Known for its forward-thinking approach and commitment to innovation, the firm integrates cutting-edge technology with design excellence to shape the built environment for the future.

SOURCE Mancini Duffy

Share this article

Hizero Wins Three Major IFA 2026 Honours as Global Leader in No-Suction Hard-Surface Cleaning

BERLIN, Sept. 8, 2026 /PRNewswire/ -- Hizero, the global leader in no-suction hard-surface cleaning appliances, has received three major independent honors at IFA 2026 in Berlin. The recognition celebrates the company's leadership in creating a smarter alternative to traditional hard-floor cleaning using noisy vacuum technology.

At the center of the awards is Hizero's latest hero product: the Glide (R700), its first autonomous robot floor cleaner. The Glide was named a 2026 IFA Innovation Award Honoree in the Best in Smart Home category, achieved the AH Best of IFA 2026 Award, and received the Digital Trends Publisher Award – IFA 2026 Innovation Winner.

One product. Three major recognitions. A true three-in-one result.

The awards underline Hizero's belief that hard floors and surfaces can be cleaned intelligently and effectively without suction. The company's message at IFA is direct: WE DON'T SUCK.

Hizero used IFA to unveil its broadest range of hard-surface cleaning products to date. The line-up includes the Glide, manual mops and other hard-floor appliances, all harnessing the Hizero signature polymer-roller technology. The system collects solid debris and manages liquid messes in the same cleaning process.

Hizero says it is not seeking to replace vacuum cleaners altogether. Carpets still need suction. But on hard floors, many households still follow a time-consuming two-step routine: sweep or vacuum first, then mop to deal with spills and dirt. Hizero is built to simplify that experience.

Its no-suction technology separates solid debris from liquid waste while cleaning, helping users manage crumbs, pet messes, spills and everyday dirt in one pass. For busy kitchens, dining rooms and hard-floor living spaces, it offers a practical alternative to the traditional mop-and-bucket routine.

"I am grateful to receive these awards and delighted that our team's years of hard work in creating a new approach to hard-surface cleaning are now being recognised in the highly competitive environment of one of the world's top-notch innovation-led tare shows," said Sam Li, CEO and founder of Hizero. "We are not against vacuuming. We are solving cleaning problems that vacuums and traditional mops cannot fix on hard floors. Our goal is smart innovation that gives people more time to enjoy living and less time cleaning."

The Glide brings Hizero's cleaning technology into autonomous floor care. It works without an app connection, making it accessible to older consumers and anyone who prefers straightforward appliances. Its automatic maintenance cycle keeps the polymer roller wet, clean and ready for use.

With traditional mops and vacuum cleaners still central to most homes, Hizero sees significant global room to grow. At IFA 2026, the company is making its case for a smarter hard-floor routine: less preparation, less hassle and more time for life.

For more information, please contact: Daisy Cai at [email protected]

Hizero PR lead Helena Liu [email protected]

Or David Noble, publicity support at RocketComms, London, UK, +44 7785302694

About Hizero

Hizero develops innovative no-suction solutions designed to wash and clean hard surfaces in homes and professional environments. The company is committed to rethinking how people care for the spaces where they live, work and play through smarter, more intuitive approaches to hard surface hygiene that frees up the user's time to make the most of life.

SOURCE Hizero

Share this article

Green Dispensary Opens Fourth Nevada Location in Las Vegas' North Valley

New Decatur and Ann location brings Green's neighborhood dispensary experience, curated Nevada cannabis selection, and convenient shopping options to northwest Las Vegas

LAS VEGAS, Sept. 8, 2026 /PRNewswire/ -- The opening expands Green's neighborhood footprint to four Nevada dispensaries, joining its existing locations in Rainbow, Hualapai, and Henderson. Each store combines a curated cannabis menu with approachable service and convenient online ordering.

About Green Dispensary

Green Cannabis Co. is a locally owned, state-licensed Nevada dispensary serving customers through four locations in Las Vegas. Green offers a curated selection of cannabis products at competitive prices, supported by knowledgeable budtenders who help customers explore options based on their individual preferences. Customers can browse live menus and place orders online for pickup or other available fulfillment options at https://greennv.com.

Cannabis products are intended only for consumers legally eligible under Nevada law. Please consume responsibly and keep cannabis products out of reach of children.

Media Contact

Andrew Kellogg  

Del Mar Advertising  

623-606-8891

[email protected]

SOURCE Green Dispensary

Share this article

Nicely Done Productions Highlights Carrier's Energy Efficient Home Comfort Solutions in New Mini-Documentary Hosted on NatGeo.com

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- Nicely Done Productions is proud to highlight Carrier's innovations in home comfort following the global climate leader's feature in Cooler Homes, Smarter Cities, part of the "Threads of Connectivity" mini-documentary series. Distributed across National Geographic's global digital platform, the program explores how connected technologies are shaping more efficient, resilient communities.

For nearly 125 years, Carrier has led innovations in heating and cooling. Today, the company is helping homeowners take greater control of comfort and energy use through connected HVAC systems, intelligent controls and digital solutions.

"As communities grow and energy demands evolve, homeowners are looking for solutions that deliver both comfort and efficiency," said Nick Arch, Vice President, General Manager, Residential Solutions, Carrier Climate Solutions Americas. "Connected technologies help homeowners make more informed decisions about their homes while improving comfort, reducing energy use and preparing for the future."

The branded mini-documentary series, hosted on NatGeo.com, explores how technology is transforming the way homes and communities operate. Carrier's episode examines how a connected ecosystem can help homeowners better understand system performance, optimize energy use and unlock the benefits of high-efficiency comfort solutions.

Heating and cooling account for a significant portion of residential energy use, creating an opportunity to improve efficiency at scale. Through connected technologies and intelligent climate solutions, Carrier is helping homeowners maximize comfort while reducing energy consumption.

"Air conditioning transformed the way people live and work," said Arch. "The next evolution is making comfort smarter through connected solutions that help homeowners get more from their systems while supporting a more sustainable future."

Click here to learn more about Carrier's connected home solutions and view Cooler Homes, Smarter Cities.

Media contact: [email protected].

About Threads of Connectivity

Threads of Connectivity is a documentary series produced by Nicely Done Productions and hosted on National Geographic's global digital platforms. The series explores the hidden systems and infrastructure that keep modern life moving, following organizations helping build and modernize the critical networks on which communities, businesses and economies depend.

SOURCE Nicely Done

Share this article

Anitoa Announces Secure Cloud Connectivity for its Portable qPCR Instruments, Unlocking Advanced Biosurveillance and AI Integration

SUNNYVALE, Calif., Sept. 8, 2026 /PRNewswire/ -- Anitoa Systems, LLC., a Silicon Valley biotechnology company and market leader in rapid, portable molecular testing hardware, today announced a major advancement in point-of-care molecular testing: the integration of comprehensive cloud connectivity and enterprise-grade security features into its highly popular line of portable qPCR instruments. By bringing the power of the cloud directly to the edge of diagnostic testing, Anitoa is empowering researchers, clinicians, and public health officials with unprecedented flexibility and data accessibility, making the fight against infectious diseases faster and more coordinated than ever before.

With this new cloud-enabled architecture, users can now seamlessly access their Anitoa instruments remotely for streamlined data collection, remote experiment setup, and real-time monitoring. The devices are easily controlled through a secure HTTPS interface via a highly customizable, cross-platform web-based application. This ensures that operators can manage their diagnostic workflows from virtually any device, anywhere in the world, without being tethered to the physical instrument in the field.

The addition of comprehensive cloud connectivity opens the door to transformative applications in global health and research. By enabling centralized cloud-based data storage, the instruments can now feed directly into large-scale data analytics platforms and support seamless AI integration. This capability is particularly vital for continuous biosurveillance, allowing health organizations to aggregate diagnostic data across multiple testing sites in real-time, accurately identify emerging pathogen trends, and deploy rapid, data-driven responses to potential outbreaks on a global scale.

Recognizing the critical importance of data privacy and the highly sensitive nature of diagnostic information, Anitoa has built robust, unyielding safeguards directly into the physical hardware. These new cloud-enabled qPCR devices feature a dedicated hardware security root of trust module that is deeply embedded within the electronics subsystem of the device. This sophisticated, hardware-level encryption ensures that every Anitoa instrument is highly tamper-proof and physically un-clonable. By securing the data from the exact moment of collection through to its final cloud transmission, Anitoa guarantees the protection of user information and patient data privacy.

At their core, Anitoa's portable qPCR devices continue to redefine the boundaries of decentralized molecular diagnostics. These extremely fast, highly cost-effective, and exceptionally portable instruments eliminate the need for cumbersome, traditional laboratory equipment. Their remarkable performance, low power consumption, and calibration-free form factor are entirely powered by Anitoa's own proprietary ultra-low-light CMOS bioimaging sensor. By combining this cutting-edge optical technology with a secure, cloud-enabled infrastructure, Anitoa is delivering on its mission to provide accessible, life-saving diagnostic systems to even the most remote corners of the globe.

About Anitoa

Anitoa Systems, a medical device technology start-up established in 2013 with headquarter in Sunnyvale, California, develops highly integrated CMOS bio-sensor for fluorescence and chemiluminescence molecular imaging. By replacing the traditional bulky and costly photon-multiplier tube (PMT) and CCD optics, Anitoa's ultra-low-light CMOS sensors enables a new generation of compact and inexpensive molecular testing platforms targeting infectious pathogens in human, in our food and environment.

For further information please contact: Li Liu, Anitoa Systems, LLC, [email protected] or 408-887-6026. www.anitoa.com

SOURCE Anitoa Systems, LLC

Share this article

- The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing.

- HBM9378/WIN378 produced significant and sustained effects on FEV1 (up to 174 mL mean increase, placebo-adjusted mean increases up to +256 mL, p=0.033), FeNO and blood eosinophils, key biomarkers that correlate with asthma exacerbations. These effects were rapid and sustained through Week 24 after a single dose of HBM9378/WIN378.

- HBM9378/WIN378 was well tolerated with favorable safety results — there were no treatment-related serious adverse events, withdrawals, or discontinuations; adverse events were balanced between active arms and placebo, with low rates of injection site reactions and anti-drug antibodies.

- The first Phase 3 study of HBM9378/WIN378 has been initiated evaluating two twice-yearly doses. A second Phase 3 trial is planned to begin in the first half of 2027.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology, and other areas, today announced that its partner, Windward Bio, has reported positive interim results from the Phase 2 portion of the POLARIS-1 clinical trial, which evaluates twice-yearly dosing of HBM9378/WIN378 in asthma.

HBM9378/WIN378 is a novel fully human, ultra-long-acting monoclonal antibody with a unique binding mode to inhibit thymic stromal lymphopoietin (TSLP). It was engineered for improved potency, extended half-life and silenced effector function. It is the only known investigational drug that blocks TSLP signaling by binding to two different sites on TSLP, interfering with the binding of TSLP to both of its co-receptors on the cell surface of epithelial cells.

POLARIS-1 is an operationally seamless, global Phase 2/3 study. The Phase 2 portion of the study is a 48-week, randomized, double-blind study evaluating three dose levels of HBM9378/WIN378 against placebo. It is designed to evaluate the pharmacokinetics, safety, immunogenicity, and pharmacodynamic activity of HBM9378/WIN378 in patients with uncontrolled moderate-to-severe asthma. The study also evaluates the effects of HBM9378/WIN378 on lung function and biomarkers of airway inflammation and informed dose selection for Phase 3 development. The Phase 2 portion of the study enrolled a total of 147 patients, exceeding the initial enrollment target of 120 patients, with the interim analysis conducted on the first 98 patients.

The interim analysis demonstrated the following at Week 24 after a single dose of HBM9378/WIN378:

- Dose-dependent mean increases in FEV1 of up to 174 mL (placebo-adjusted mean increase up to 256 mL, p=0.033).

- Dose-dependent mean reductions in FeNO of up to 24 ppb (or -43% change, p=0.006).

- Reductions in mean blood eosinophil count (EOS) of up to 200 cells/µL (or -51% change, p0.0001).

- Near maximal effects seen as early as Week 2 and sustained through Week 24.

Notes: FEV1 (forced expiratory volume in one second) is a key measure of lung function. FeNO (fractional exhaled nitric oxide) and EOS are key markers of inflammation that correlate with exacerbations.

HBM9378/WIN378 was well tolerated with favorable safety results, and there were no treatment-related serious adverse events, withdrawals, or discontinuations observed as of the cut-off date. Adverse events were balanced between active arms and placebo. Less than 1% of participants experienced injection site reactions, and 2% developed anti-drug antibodies (ADAs), a measure of immunogenicity. ADAs had no impact on the pharmacology of HBM9378/WIN378. The results of the interim analysis and population pharmacokinetic modeling support the potential of twice-yearly dosing of HBM9378/WIN378.

"We are very encouraged by the positive Phase 2 results of HBM9378/WIN378 and its continued progression into Phase 3 development," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. "HBM9378/WIN378 is an ultra-long-acting fully human monoclonal antibody against TSLP generated from our H2L2 Harbour Mice® platform. The significant and sustained improvements in lung function and airway inflammation observed with a single dose, together with its potential for twice-yearly dosing, further reinforce the therapeutic potential of this molecule. We are fully confident in the clinical potential of this novel biotherapeutic."

Two twice-yearly doses have been selected for the Phase 3 portion of POLARIS-1, which is designed to evaluate the effect of HBM9378/WIN378 on annualized asthma exacerbation rate and other key efficacy measures in patients with severe asthma. The Phase 3 portion of the study has been initiated by Windward Bio who plans to begin a second Phase 3 study, POLARIS-2, in the first half of 2027. Data from the Phase 2 portion of POLARIS-1 will be presented at an upcoming medical congress.

About POLARIS-1 Study

POLARIS-1 (NCT07120503) is an operationally seamless, global Phase 2/3 study of HBM9378/WIN378 in adults with uncontrolled asthma conducted by Windward Bio. The Phase 2 portion is a randomized, double-blind study evaluating three dose levels of HBM9378/WIN378 administered subcutaneously against placebo, with primary objectives of characterizing pharmacokinetics, safety, immunogenicity and pharmacodynamic activity, as well as informing dose selection for Phase 3. The Phase 3 portion is evaluating two twice-yearly doses of HBM9378/WIN378 against placebo, with a primary endpoint of annualized asthma exacerbation rate in patients with severe asthma.

About HBM9378/WIN378

HBM9378/WIN378 is a novel fully human, ultra-long-acting monoclonal antibody with a unique binding mode to inhibit thymic stromal lymphopoietin (TSLP). This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma, chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. HBM9378/WIN378 was engineered for improved potency, extended half-life and silenced effector function. It is the only known investigational drug that blocks TSLP signaling by binding to two different sites on TSLP, interfering with the binding of TSLP to both of its co-receptors on the cell surface of epithelial cells. Phase 2 interim results support the potential of twice-yearly dosing. HBM9378/WIN378 produced significant, sustained and dose-dependent increases in FEV1, a measure of lung function, together with significant and sustained reductions in FeNO and blood eosinophils — key markers that correlate with asthma exacerbations. HBM9378/WIN378 is being evaluated in the global Phase 2/3 POLARIS-1 study in asthma and the Phase 2 SIRIUS study in COPD, with a second pivotal Phase 3 asthma trial, POLARIS-2, planned to begin in the first half of 2027. HBM9378/WIN378 (also known as SKB378) started as a co-development project jointly conducted by Harbour BioMed and Kelun-Biotech, with both parties equally sharing global rights. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for this molecule from Harbour BioMed (also known as HBM9378) and Kelun-Biotech (also known as SKB378).

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUS™) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIx™ AI platform, accelerating the development of innovative therapies.

By integrating Harbour Mice®, HBICE®, HCAb PLUS™, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep discovery, development and commercial expertise, developing ultra-long-acting antibodies for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. The Company is advancing a pipeline of potentially differentiated biologics targeting clinically validated molecular pathways, with the goal of improving clinical outcomes while reducing treatment burden through less frequent dosing. Windward Bio's lead program is WIN378, a novel fully human monoclonal antibody engineered for improved potency, extended half-life and silenced effector function, targeting TSLP. WIN378 is in clinical development for asthma and COPD. The Company's second program is WIN027, an ultra-long-acting, humanized bi-specific antibody targeting TSLP and IL-13 in development for respiratory and dermatologic diseases.

Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo

NEW YORK and SUZHOU, China, Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Industrial"), a subsidiary of its partner Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"), has received approval from China's National Medical Products Administration (NMPA) to conduct a Phase II/III adaptive seamless design clinical trial of AC-201 tablets (Fosun development code: FXS5626) for the treatment of non-segmental vitiligo. Fosun Pharma Industrial plans to initiate the relevant clinical trial for this indication in mainland China once the necessary conditions are met.

About AC-201

AC-201 is a novel, highly selective and potent oral small-molecule inhibitor of TYK2/JAK1 that binds to the pseudo kinase domain (JH2) of TYK2/JAK1, with minimal effect on the JAK2/JAK2 signaling pathway. It is currently being developed to treat immune mediated inflammatory diseases.

About Accro Bioscience

Accro Bioscience (Suzhou) Limited is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for inflammatory and autoimmune diseases, by targeting molecular mechanisms of regulatory cell death. The company's robust pipeline of first- and best-in-class compounds offers the potential for innovative, paradigm-shifting therapies.

About Fosun Pharma

Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem.

Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia.

Looking ahead, guided by the strategy of "Innovation Driven, Deep Globalization, and AI Embracement", Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health.

SOURCE Accro Bioscience (Suzhou) Limited

Share this article

A nationwide brand refresh that unlocks personal empowerment

ALPHARETTA, Ga., Sept. 8, 2026 /PRNewswire/ -- As eyewear continues to evolve from a functional necessity into a powerful expression of style, National Vision Holdings, Inc. (NASDAQ: EYE) is unveiling a reimagined Eyeglass World designed to meet the expectations of today's digitally engaged, style conscious consumer. Developed in partnership with creative agency VML, the transformation pairs an elevated brand identity and a dynamic national creative campaign built around a simple truth: "Change Your Glasses. Change Your World." Together, they celebrate how the power of eyewear can shape confidence, style, and perspective.

This evolution marks a new chapter for Eyeglass World, positioning the brand as a more digital, curated, and elevated optical destination where fashion, accessibility, and experience converge. Eyeglass World introduces a warmer, more refined brand expression, a curated, style-forward eyewear assortment, with an unmatched connected customer experience. Through trusted guidance and a customer-first approach, the brand empowers consumers to make confident eyewear decisions while delivering a boutique-inspired experience.

At the heart of this refresh is "Change Your Glasses. Change Your World.", a campaign rooted in the belief that eyewear has the power to transform not only how people look, but how they feel. Stepping into a style-forward future, the launch film brings this to life by following a woman in a mirror maze trying on different versions of herself with every new pair of glasses. Proving that the right frames don't just change your style, they reshape your outlook, your confidence, and how you see your world.

"This is a complete reinvention of the brand to meet the expectations of today's style-focused consumers," said Joe VanDette, Chief Brand and Marketing Officer at National Vision. "In partnership with VML, we have built a brand personality and visual system that celebrates personal expression. We are showcasing our curated selection of frames and making it easier than ever for customers to shop their way - whether they use virtual try on and buy online or finalize their perfect look in-store."

"We wanted the creative to celebrate the fact that people aren't static, we're multi-faceted, and constantly changing," said Tom Murphy, Chief Creative Officer at VML North America. "There is a frame for every version of who you are and who you want to be. Our new visual identity and launch work showcase how an elevated, curated pair of glasses can instantly shift your confidence, your style, and your outlook."

The new Eyeglass World is rolling out nationwide across digital video, social media, and through strategic influencer partnerships. The brand's message of change also served as the muse for an original single, "Change Your World" by Spencer Ludwig, in partnership with Trumpet Records. The track, which serves as the soundtrack to the relaunch, debuted on all streaming platforms earlier this month.

About National Vision Holdings, Inc. National Vision Holdings, Inc. (NASDAQ: EYE) is one of the largest optical retail companies in the United States with over 1,200 stores in 40 states and Puerto Rico. With a mission of helping people by making quality eye care and eyewear more affordable and accessible, the company operates four retail brands: America's Best, Eyeglass World, and Vista Optical inside select Fred Meyer stores and on select military bases, and an e-commerce website DiscountContacts.com, offering a variety of products and services for customers' eye care needs. For more information, please visit www.nationalvision.com.

About VML VML is a leading creative company that combines brand experience, customer experience, and commerce, creating connected brands to drive growth. VML is celebrated for its innovative and award-winning human-first work for clients, recently named Campaign's Global Network of the Year and ranked No. 2 Creative Network of the Year at Cannes Lions. VML's global network spans more than 55 markets with principal offices in Buenos Aires, Kansas City, London, New York, São Paulo, Shanghai, and Singapore.

VML is part of WPP, the trusted growth partner for the world's leading brands. Powered by exceptional talent and our agentic marketing platform WPP Open, WPP unites cutting-edge media intelligence and data solutions, creativity, production, enterprise solutions and expert strategic counsel.

For more information, please visit www.vml.com and follow along on LinkedIn #WeAreVML

Share this article

FSA Store® Celebrates 16 Years of Helping Customers Maximize Their Funds with Its Biggest FSA Day™ Sale Yet

DALLAS, Sept. 8, 2026 /PRNewswire/ -- FSA Store®, the first and leading online retailer dedicated to helping FSA account holders maximize their pre-tax dollars, is celebrating sixteen years of offering a 100% eligible shopping experience with the return of FSA Day™. This special savings event—taking place September 14-16, 2026 as the annual benefits open enrollment season gets underway—invites the more than 35 million current FSA account holders to enjoy significant deals while exploring the many eligible ways their FSA can be used to support their health.

"Sixteen years ago, we launched FSA Store® with a single mission: to simplify pre-tax health benefits for individuals and families." said Keri Kaiser, Chief Revenue Officer at Health-E Commerce, parent company of FSA Store®. "FSA Day™ is a celebration of how we've evolved that promise, expanding from everyday health products into vetted telehealth services, all 100% eligible and backed by the education and tools customers need to make the most of their funds."

Featuring limited-time deals on a wide range of eligible products and services, FSA Day™ is the perfect time for FSA account holders to explore the breadth of what their funds can cover—from OTC medicines, to the skin and suncare brands they love, to the hi-tech health trackers they've been eyeing, to GLP-1 treatments through Patiently™—and enjoy exceptional savings while doing so.

FSA Store® will also host a Win Your Cart Sweepstakes* in the lead-up to the event, with 16 winners receiving a $500 store credit to spend on items in their cart. Entries close September 13 at 11:59 p.m. ET, and winners will be notified September 14, 2026.

FSA users collectively forfeit an estimated $4 billion each year, often because they don't know how to use their funds or what products and services are eligible. To address this need, FSA Store® also offers a free FSA Learning Center that features eligibility discovery and planning tools, including:

- The Eligibility List™: a comprehensive, searchable list that makes it easy to find all the eligible products or services consumers need. The Eligibility List also helps when planning contributions for the upcoming year.

- FSA Spending Calculator™: This interactive tool helps account holders estimate how much they should contribute to their FSA and how much they can save in taxes by enrolling in this benefit.

- That's Covered?: Articles designed to help consumers learn about the Surprisingly Eligible™ ways to spend their FSA funds, from menstrual care to health trackers to weight loss, and more.

What is an FSA? An FSA, or flexible spending account, is a tax-advantaged account that consumers can enroll in through their employer-sponsored benefits program. Employees, employers or both can contribute to the account pre-tax. For Employees, this reduces their taxable income and helps them pay for a wide range of qualified medical expenses. FSA eligible expenses are determined by the Internal Revenue Service. FSA funds are "use-it-or-lose-it," meaning unused balances may be forfeited at the end of the plan year, unless an employer chooses to offer a rollover or grace period option. This potential forfeiture of unused funds makes FSA education and 100% eligible shopping all the more essential for FSA account holders looking to maximize their health and financial wellness.

Win Your Cart: official rules at https://fsastore.com/fsa-day-rules.html; void where prohibited. Cart must be built (not purchased) by 9/13/26, 5:59 AM ET.

For more information, visit FSA Store® or contact [email protected].

About Health-E Commerce®

Health-E Commerce® is the owner of the brands FSA Store® and HSA Store®, online stores that simplify pre-tax health spending for more than 70 million consumers enrolled in these accounts. Behind 100% guaranteed eligible products, vetted telehealth services, and the company's own Caring Mill® line of everyday health essentials at value pricing, these stores offer guesswork-free shopping, plus the tools and education account holders need to make the most of their funds. In 2026, the company introduced Patiently™, its fully owned virtual care experience, helping FSA and HSA participants get access to personalized prescription treatment by licensed providers. Beyond its consumer-facing brands, Health-E Commerce works across the pre-tax health benefits landscape, maintaining a regularly updated Eligibility List™, building partnerships with third-party administrators, and advancing consumer advocacy.

SOURCE Health-E Commerce

Share this article